Soligenix (SNGX) Encourages Stockholders to Vote "FOR" Reverse Stock Split

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote "FOR" a Reverse Stock Split. The Company and its Board of Directors believe it is important to maintain the listing of the Common Stock on The Nasdaq Capital Market ("Nasdaq"). "Failure to maintain our listing on Nasdaq and meet Nasdaq's listing requirements has the potential to detrimentally impact our ability to attract the necessary institutional support to advance the HyBryte™ Phase 3 confirmatory trial and our other pipeline clinical programs to important value inflection points necessary to secure potential partnerships and/or additional non-dilutive government funding to build shareholder value," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.

Eligible stockholders may vote by contacting the Company's proxy solicitor, Alliance Advisors, at 1-833-782-7145. Only stockholders at the close of business on the record date, April 10, 2024, will be eligible to participate. Even stockholders as of April 10, 2024 who have subsequently sold their shares are eligible and encouraged to vote.

Please refer to the official proxy materials for further details on each proposal, this can be found at https://ir.soligenix.com/sec-filings.

You May Also Be Interested In

• Aurinia settles patent dispute with Teva over generic voclosporin
• IsoEnergy and Disa Technologies close deal to form Disa Uranium Corp
• Saba Capital renames closed-end funds ETF, ticker unchanged